These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152 [TBL] [Abstract][Full Text] [Related]
28. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958 [TBL] [Abstract][Full Text] [Related]
29. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610 [TBL] [Abstract][Full Text] [Related]
30. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288 [TBL] [Abstract][Full Text] [Related]
31. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Zhu Y; Shah K Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109 [TBL] [Abstract][Full Text] [Related]
32. A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations. Ho KT; Chen PF; Chuang JY; Gean PW; Hsueh YS Life Sci; 2022 Jan; 288():120176. PubMed ID: 34848192 [TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor as a therapeutic target in glioblastoma. Kalman B; Szep E; Garzuly F; Post DE Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987 [TBL] [Abstract][Full Text] [Related]
34. TNF Inhibitor Pomalidomide Sensitizes Glioblastoma Cells to EGFR Inhibition. Luo Z; Wang B; Liu H; Shi L Ann Clin Lab Sci; 2020 Jul; 50(4):474-480. PubMed ID: 32826244 [TBL] [Abstract][Full Text] [Related]
35. Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation of EGFR for the Clinical Treatment of Glioblastoma. Bhrdwaj A; Abdalla M; Pande A; Madhavi M; Chopra I; Soni L; Vijayakumar N; Panwar U; Khan MA; Prajapati L; Gujrati D; Belapurkar P; Albogami S; Hussain T; Selvaraj C; Nayarisseri A; Singh SK Appl Biochem Biotechnol; 2023 Aug; 195(8):5094-5119. PubMed ID: 36976507 [TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Lassman AB; Aldape KD; Ansell PJ; Bain E; Curran WJ; Eoli M; French PJ; Kinoshita M; Looman J; Mehta M; Muragaki Y; Narita Y; Ocampo C; Roberts-Rapp L; Song M; Vogelbaum MA; Walenkamp AME; Wang TJC; Zhang P; van den Bent MJ J Neurooncol; 2019 Aug; 144(1):205-210. PubMed ID: 31273577 [TBL] [Abstract][Full Text] [Related]
37. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H Cells; 2019 Apr; 8(4):. PubMed ID: 31013819 [TBL] [Abstract][Full Text] [Related]
38. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma. Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930 [TBL] [Abstract][Full Text] [Related]
39. A gain of function paradox: Targeted therapy for glioblastoma associated with abnormal NHE9 expression. Pall AE; Juratli L; Guntur D; Bandyopadhyay K; Kondapalli KC J Cell Mol Med; 2019 Nov; 23(11):7859-7872. PubMed ID: 31532058 [TBL] [Abstract][Full Text] [Related]
40. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Eller JL; Longo SL; Hicklin DJ; Canute GW Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]